Skip to main content
SpringerLink
Log in

Psychotic Disorder Induced by Oxybutynin

Presentation of Two Cases

  • Case Reports
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Anticholinergic agents are muscarinic receptor antagonists that suppress the activity of the acetylcholine system in the brain. Some of these agents also increase the concentration of dopamine in the synaptic cleft, which may result in psychotic symptoms. Oxybutynin is an antimuscarinic drug that may have adverse effects on the CNS, including memory impairment, confusion, delirium and hallucinations in elderly patients. To date, several case reports have been published about the association between oxybutynin and psychotic symptoms in elderly subjects, but we were unable to find any case reports describing oxybutynin-induced psychotic disorders in young people. Here we report on two patients, a 7-year-old boy and a 21-year-old man, who developed a brief psychotic disorder that may have been caused by oxybutynin.

The first patient was kept under observation with vital functions supported but no medication. All his psychotic symptoms regressed and his general condition improved. The second patient was treated with olanzapine 10 mg/ day. His psychotic symptoms resolved within 3 weeks. Our two case reports provide evidence that oxybutynin may induce psychotic disorders, and in younger patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Malkowicz SB, Wein AJ, Ruggieri MR, et al. Comparison of calcium antagonist properties of antispasmodic agents. J Urol 1987; 138(3): 667–70

    PubMed  CAS  Google Scholar 

  2. Int’Veld BA, Kwee-Zuiderwijk WJ, van Puijenbroek EP, et al. Neuropsychiatric adverse effects attributed to use of oxybutynin. Ned Tijdschr Geneeskd 1998; 142(11): 590–2

    Google Scholar 

  3. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. No 34. London: BMA,RPS, 1997

    Google Scholar 

  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994

    Google Scholar 

  5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45

    Article  PubMed  CAS  Google Scholar 

  6. Guy W. ECDEU assessment manual for psychopharmacology — revised (DHEW Publ. No. ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976: 218-22

  7. Calne DB. Treatment of Parkinson’s disease. N Engl J Med 1993; 329: 1021–7

    Article  PubMed  CAS  Google Scholar 

  8. Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315: 1363–4

    Article  PubMed  CAS  Google Scholar 

  9. Adcock EW. Cyclopentolate (Cyclogyl) toxicity in pediatric patients. Pediatr Pharmacol Ther 1971; 79: 127–9

    Google Scholar 

  10. Ananth JV, Jain RC. Benztropine psychosis. Can Psychiatr Assoc J 1973; 18: 409–14

    PubMed  CAS  Google Scholar 

  11. Anath JV, Lehman HE, Ban TA. Toxic psychosis induced by benzhexol hydrochloride. CMAJ 1970; 103: 771

    Google Scholar 

  12. Bernstein S, Leff R. Toxic psychosis from sleeping medicines containing scopolamine. N Engl J Med 1967; 277: 638–9

    Article  PubMed  CAS  Google Scholar 

  13. Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostigmine. JAMA 1968; 206: 1963–5

    Article  PubMed  CAS  Google Scholar 

  14. Gowdy JM. Stramonium intoxication: review of symptomatology in 212 cases. JAMA 1972; 221: 585–7

    Article  PubMed  CAS  Google Scholar 

  15. Granacher RP, Baldessarini RJ. Physostigmine treatment of delirium induced by anticholinergics. Am Fam Physician 1976; 13: 99–103

    PubMed  CAS  Google Scholar 

  16. Granacher RP, Baldessarini RJ. Physostigmine: its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry 1975; 32: 375–82

    Article  PubMed  CAS  Google Scholar 

  17. Greenblatt DJ, Shader RI. Anticholinergics. N Engl J Med 1973; 288: 1215–9

    Article  PubMed  CAS  Google Scholar 

  18. Heiser JF, Gillin JC. The reversal of anticholinergic druginduced delirium and coma with physostigmine. Am J Psychiatry 1971; 127: 1050–4

    PubMed  CAS  Google Scholar 

  19. Johnson CE. Mystical force of the nightshade. Int J Neuropsychiatry 1967; 3: 268–75

    PubMed  CAS  Google Scholar 

  20. Mikolich JR, Paulson GW, Cross CJ. Acute anticholinergic syndrome due to jimson seed ingestion. Ann Intern Med 1975; 83: 321–5

    PubMed  CAS  Google Scholar 

  21. Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics 1973; 52: 449–51

    PubMed  CAS  Google Scholar 

  22. Shader RI, Greenblatt DJ. Belladonna alkaloids and synthetic anticholinergics: uses and toxicity. In: Shader RI, editor. Psychiatric complications of medical drugs. New York: Raven Press, 1972: 102–47

    Google Scholar 

  23. Shafer DJ, Allen RP. The central effects of scopolamine in man. Biol Psychiatry 1971; 3: 347–55

    Google Scholar 

  24. Ullman KC, Groh RH, Wolff FW. Treatment of scopolamineinduced delirium. Lancet 1970; I: 252

    Article  Google Scholar 

  25. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47(4): 337–43

    Article  PubMed  CAS  Google Scholar 

  26. Jonville AP, Dutertre JP, Autret E, et al. Effets indésirables du chlorure d’oxybutynine (Ditropan). Bilan de l’enquete officielle des Centres Régionaux de Pharmacovigilance. Therapie 1992; 47: 389–92

    PubMed  CAS  Google Scholar 

  27. Valsecia ME, Malgor LA, Espíndola JH, et al. New adverse effect of oxybutynin: ‘night terror’ [letter]. Ann Pharmacother 1998; 32: 506

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Written consent was obtained from the patients for publication of the patients’ details. This report did not receive any funding and the authors have no potential conflicts of interest that are directly relevant to the contents of this report.

Author information

Authors and Affiliations

  1. Psychiatry Service, Tatvan Military Hospital, Tatvan Asker Bastabipligi Ufuk Cad, 13200, Tatvan, Bitlis, Turkey

    Murat Gulsun, Murat Pinar & Unal Sabanci

Authors
  1. Murat Gulsun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murat Pinar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Unal Sabanci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murat Gulsun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gulsun, M., Pinar, M. & Sabanci, U. Psychotic Disorder Induced by Oxybutynin. Clin. Drug Investig. 26, 603–606 (2006). https://doi.org/10.2165/00044011-200626100-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626100-00007

Keywords

Search

Navigation